Larisa Yun-Boevna Pak’s story matters not because of the criminal case that overshadowed the final years of her life. It matters because of everything that came before. For more than three decades, she worked in Kazakhstan’s healthcare and pharmaceutical sector, rising from a pharmacy inspector to head of the Pharmacy Committee. She helped build the rules, institutions and regulatory framework that underpin the country’s modern pharmaceutical system. Her contribution was never about public attention. It was about creating a system that safeguards the health of millions every day.
Larisa Pak belonged to the generation that had to build Kazakhstan’s public institutions almost from scratch after independence. The country needed its own medicines policy, quality control system for pharmaceuticals and medical devices, regulatory framework, market authorization procedures, and mechanisms linking the state with manufacturers, pharmacies, hospitals and expert organizations.
It was painstaking work that rarely made headlines. Yet without it there are no safe medicines, no public trust, and no effective protection for patients.
That was the part of government where Larisa Pak spent her career
She graduated from the Faculty of Pharmacy at the Almaty State Medical Institute in 1980. She began as a pharmacy inspector in the Zhezkazgan Regional Pharmacy Administration, later heading the organizational and pharmaceutical department before moving to Almaty’s state pharmaceutical association “Pharmatsiya,” where she held positions ranging from pharmacy technologist to deputy head of its organizational and pharmaceutical division.
She later led the Information and Marketing Center and, from 1998, worked at the state enterprise Dari-Darmek Center for Medicines, first as head of pharmaceutical regulation and later as deputy director general. In 2002 she became Deputy Chair of the Pharmacy, Pharmaceutical and Medical Industry Committee at the Ministry of Health, later serving as Acting Chair of the Pharmacy Committee.
Her career mattered because she did not arrive in regulation through politics or administrative appointments alone. She understood every layer of the system — pharmacies, manufacturing, regulation, expert review and public administration. She knew how decisions made in government offices ultimately affected pharmacies, hospitals, manufacturers, doctors and patients.
In pharmaceuticals, that perspective is indispensable. Regulation is not simply about issuing orders. It requires understanding the entire chain — from product registration and quality control to procurement, distribution and clinical use.
Society rarely notices people who build such systems. Patients collect medicines from pharmacies, receive treatment in hospitals and trust doctors’ prescriptions. Behind those everyday interactions stands an invisible infrastructure of trust: people who approve medicines, verify quality, write the rules and protect patients from weak oversight and market failures.
That infrastructure rarely appears in headlines. But it is what separates a functioning healthcare system from a collection of disconnected decisions.
Larisa Pak was one of the people who built that infrastructure in Kazakhstan
During the 1990s and early 2000s, Kazakhstan’s pharmaceutical sector underwent a difficult transformation. After the collapse of the Soviet system, the country had to redesign how medicines, medical devices, quality, safety, manufacturing, imports and market regulation would be governed.
Opening the market was not enough. The challenge was ensuring that the market itself would never become a threat to patients. That required laws, institutions, qualified professionals and public officials capable of thinking beyond immediate problems.
Larisa Pak worked at the center of that effort
Her career was closely tied to the creation of Kazakhstan’s modern pharmaceutical regulatory system. The phrase may sound technical, but its public value is anything but. Pharmaceutical regulation determines which medicines reach patients, how their quality is verified, whether safety standards are enforced, how manufacturers operate and how well patients are protected.
In Kazakhstan, medicines usually become a national issue only during crises — when shortages emerge, prices rise, procurement comes under scrutiny or patients cannot access treatment. But resilient pharmaceutical systems are not built during crises.
They are built years in advance through institutions, expertise, regulation, oversight and professional culture. That was precisely the work Larisa Pak devoted herself to.
Former colleagues remember her as an outstanding professional, a wise and fair leader, and someone who dedicated her life to the development of Kazakhstan’s pharmaceutical sector. In an industry where decisions are technical, complex and often unpopular, professional credibility cannot be gained through titles alone. It is earned over decades through expertise, discipline and accountability.
Quality, safety and access remained central throughout her career. These principles are inseparable. Medicines cannot be accessible without quality control. They cannot be safe without predictable rules. Domestic manufacturing cannot develop under unstable regulation. Patients cannot be protected if government and industry fail to speak the same professional language.
For Larisa Pak, pharmaceutical policy was part of public health, not simply an administrative function
That had lasting importance for Kazakhstan.
As the country built its national pharmaceutical market, joined international integration processes and aligned its regulatory framework with global standards, Larisa Pak represented Kazakhstan within the Eurasian Economic Community. She contributed to harmonized pharmaceutical regulation, strengthened regional healthcare cooperation and supported Kazakhstan’s preparations for accession to the World Trade Organization.
This became another defining chapter of her career. Kazakhstan could never develop pharmaceutical regulation in isolation. Medicines are inseparable from international standards, trade, manufacturing, imports, registration and mutual recognition. A country building new institutions needed specialists equally fluent in law, pharmaceuticals, healthcare and international obligations.
Larisa Pak was one of them
She worked in a field where regulatory failure can become a personal tragedy for patients. Poor-quality medicines, weak oversight, opaque rules and inadequate standards are not abstract risks. They affect lives.
That is why contributions to pharmaceutical regulation should not be measured by titles alone, but by the resilience they create. Clear rules, strong scientific expertise, effective quality control and institutional memory are public goods.
Larisa Pak helped build exactly that
Her work was recognized through numerous state and professional awards, including the honorary badge Excellence in Healthcare of the Republic of Kazakhstan, the For Distinguished Service Medal, the Contribution to Healthcarebadge, a Prime Minister’s Letter of Appreciation, the medal For Contribution to the Creation of the Eurasian Economic Union, and numerous certificates of merit.
Their significance lies not in ceremony, but in the recognition by both the state and the professional community of her contribution to healthcare, pharmaceutical regulation and Kazakhstan’s international standing. That is why her story belongs in the In the Shadow of Recognition series.
It is not simply the story of a woman who held senior office. Nor is it only the story of someone who endured criminal prosecution before ultimately being exonerated. It is the story of a woman whose work became so deeply embedded in public institutions that society almost forgot who helped build them. Her achievements were measured not by applause but by the state’s ability to better protect the health of its citizens.
In that sense, her life was dedicated to public service in its most practical form. She did not treat patients at the bedside. But her work influenced which medicines reached them, how those medicines were approved, how quality was controlled and how effectively the state protected public health. It was a quieter form of service. But no less important.
Today Kazakhstan once again views pharmaceuticals as a strategic industry. Industrial policy, domestic manufacturing, long-term procurement, medical devices, exports, clinical research, GMP standards, supply chain resilience and trust in regulation dominate today’s agenda.
None of these priorities emerged overnight. Their foundations were laid decades ago.
Larisa Pak was among those who built them
That is why her name deserves to be remembered not as a symbol of tragedy, but as part of Kazakhstan’s institutional memory. Her story also speaks to the role of women in Kazakhstan’s public administration.
Women’s contributions to institution-building often receive less recognition than those of politicians or senior public figures, particularly in technical fields such as pharmaceuticals, healthcare, standardization, scientific expertise and regulation.
Yet these are precisely the areas where the quality of government is forged. Many women who shaped these systems never became public figures, despite influencing the lives of millions.
Larisa Pak was one of them
She was never a media personality and never sought political capital through public visibility. Her strength lay elsewhere — deep professional expertise, discipline, quiet leadership and the ability to make decisions where the cost of failure was exceptionally high. These are often the lives that remain in the shadows.
The events of 2017 should not erase that legacy. Yet they cannot be ignored.
In July 2017, while serving as Acting Chair of the Ministry of Health’s Pharmacy Committee, Larisa Pak was detained on allegations of accepting bribes reportedly totaling KZT 10 million. Several other officials were detained alongside her. Kazakhstan’s Anti-Corruption Service alleged systematic bribery, lobbying for pharmaceutical companies and misappropriation of public funds through inflated medicine procurement under the guaranteed package of free medical care.
The accusations received widespread public attention. For someone who had spent decades serving the system, they struck not only at her freedom but at her reputation. Her detention was repeatedly extended before being replaced with house arrest after roughly five months in pre-trial custody. The case was later dismissed for lack of evidence of a criminal offense.
Larisa Pak died on 6 July 2019. On 7 December 2020, Kazakhstan’s Anti-Corruption Agency formally rehabilitated her, confirming that no criminal offense had occurred. In 2022, the agency opened an investigation into alleged unlawful investigative methods used by former officers involved in her case, publicly apologized to her family and expressed official condolences. That conclusion matters. But it should not define her life.
The state acknowledged that no crime had been committed, apologized and restored her legal reputation. If society remembers only the prosecution while forgetting decades of public service, that restoration remains incomplete. Legal rehabilitation restores a person’s status. Public memory should restore their true legacy.
That is why any account of Larisa Pak should begin not with her arrest, but with her contribution
With what she built for Kazakhstan. With how her work affected ordinary citizens who never knew her name. With the understanding that pharmaceutical regulation is not merely about medicines, but about national resilience. Behind every quality standard, every regulatory requirement and every approval process stand real people.
Larisa Pak was one of them
The greatest lesson of her life is that nations are built not only by presidents, ministers or celebrated reformers. They are also built by professionals like Larisa Pak — people who master their field, create institutions, establish rules and leave behind systems that continue working long after they are gone.
Perhaps that is precisely why their contributions are so easily overlooked. They disappear into the normal functioning of institutions. Only when they are absent do we realize how much depended on them.
Larisa Pak deserves her place in the history of Kazakhstan’s healthcare system not because of what happened in the final years of her life, but because of everything she accomplished beforehand — decades of public service, her role in shaping pharmaceutical regulation, improving medicine quality and safety, representing Kazakhstan internationally and building a professional school remembered by colleagues who saw in her not simply an official, but a true public servant.
That is the purpose of the In the Shadow of Recognition series. It tells the stories of women whose work mattered more than their public profile. Women who transformed entire sectors through daily decisions rather than slogans. Women who built institutions while others attracted attention. Kazakhstan should remember them because honest national history depends on it.
The country’s pharmaceutical system did not emerge on its own. It was built by specialists, regulators, pharmacists, lawyers, physicians and public servants who accepted responsibility during difficult years.
Larisa Yun-Boevna Pak was among them
Her name deserves to stand not as a footnote to a criminal case, but alongside those who built Kazakhstan’s modern healthcare system. That is what true remembrance looks like. Not pity. Not retrospective justification. But recognition of what mattered most. A woman who devoted her life to the safety of medicines and the health of her country deserves to be remembered for a legacy that continues to serve Kazakhstan long after she is gone.
Lina Yegil kizi, expert of the EconomyKZ.org portal
